IMR Press / EJGO / Volume 39 / Issue 4 / DOI: 10.12892/ejgo4206.2018
Open Access Original Research
miR-145 regulates proliferation and chemotherapy sensitivity of ovarian carcinoma
Show Less
1 Department of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, China
Eur. J. Gynaecol. Oncol. 2018 , 39(4), 634–640; https://doi.org/10.12892/ejgo4206.2018
Published: 10 August 2018
Abstract

Previous work showed that miR-145 is downregulated in human serous epithelia ovarian carcinoma (SEOC) tissue and SKOV3 cells. However, the molecular mechanisms of miR-145 used to regulate ovarian proliferation and chemotherapy sensitivity remain to be determined. The present research demonstrate that miR-145 inhibit SKOV3 cells proliferation and promote chemotherapy sensitivity to paclitaxel according to MTT assay. MiR-145 inhibits Mucin1 (MUC1) post-transcriptional expression by binding to its 3'-untranslated region (UTR). The epithelial mesenchymal transition (EMT) marker E-cadherin (E-cad), which is downstream molecule of MUC1, is promoted by miR-145 overexpression. Furthermore, the E-cad protein level is inversely correlated with the expression of MUC1 in SKOV3 cells. It showed that promotion of E-cad signaling induced by miR-145 was released by MUC1 inhibition. Taken together, miR-145 serves as a tumor suppressor which can upregulate E-cad expression by targeting MUC1, leading to the inhibition of tumor proliferation and chemotherapy sensitivity. The miR-145 could be a rationale for therapeutic applications in ovarian carcinoma in the future.
Keywords
Ovarian carcinoma
miR-145
MUC1
Proliferation
Chemotherapy sensitivity
Share
Back to top